Ragweed mix vaccine - Woodmont Pharmaceuticals

Drug Profile

Ragweed mix vaccine - Woodmont Pharmaceuticals

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Woodmont Pharmaceuticals
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Allergic conjunctivitis; Seasonal allergic rhinitis

Most Recent Events

  • 01 Mar 2017 Phase-I clinical trials in Allergic conjunctivitis (In adolescents, In adults) in USA (Intralymphatic) (NCT03038971)
  • 01 Mar 2017 Phase-I clinical trials in Seasonal allergic rhinitis (In adolescents, In adults) in USA (Intralymphatic) (NCT03038971)
  • 07 Oct 2016 Preclinical trials in Seasonal allergic rhinitis in USA (Intralymphatic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top